Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. - Wikidata - wikimedia - TriplyDB

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study.

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study.

http://www.wikidata.org/entity/Q34515400

about

Prognosis of the individual course of disease--steps in developing a decision support tool for Multiple Sclerosis Defining the clinical course of multiple sclerosis: the 2013 revisions.Cost-Effectiveness of Disease-Modifying Therapies in Multiple Sclerosis Treatment with disease modifying drugs for people with a first clinical attack suggestive of multiple sclerosis Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis Optical coherence tomography: a window into the mechanisms of multiple sclerosis Disease-modifying treatments for multiple sclerosis - a review of approved medications Optimizing the initial choice and timing of therapy in relapsing-remitting multiple sclerosis Treatment strategies for multiple sclerosis: When to start, when to change, when to stop?Multiple sclerosis in the Arabian Gulf countries: a consensus statement Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosis Review of the pharmacoeconomics of early treatment of multiple sclerosis using interferon beta The mechanism of action of interferon-β in relapsing multiple sclerosis Development of oral immunomodulatory agents in the management of multiple sclerosis Establishing long-term efficacy in chronic disease: use of recursive partitioning and propensity score adjustment to estimate outcome in MS Country, sex, EDSS change and therapy choice independently predict treatment discontinuation in multiple sclerosis and clinically isolated syndrome Risk Factors for Poor Adherence to Betaferon® Treatment in Patients with Relapsing-Remitting Multiple Sclerosis or Clinically Isolated Syndrome Measles IgG antibody index correlates with T2 lesion load on MRI in patients with early multiple sclerosis Current and emerging therapies in multiple sclerosis: a systematic review Differential diagnosis of suspected multiple sclerosis: a consensus approach Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.New magnetic resonance imaging biomarkers for the diagnosis of multiple sclerosis.Guidelines from The Italian Neurological and Neuroradiological Societies for the use of magnetic resonance imaging in daily life clinical practice of multiple sclerosis patients.A comparison of sagittal short T1 inversion recovery and T2-weighted FSE sequences for detection of multiple sclerosis spinal cord lesions.Role of magnetic resonance imaging in the diagnosis and monitoring of multiple sclerosis: consensus report of the White Matter Study Group.Randomized study of once-weekly interferon beta-1la therapy in relapsing multiple sclerosis: three-year data from the OWIMS study.Imaging of multiple sclerosis: role in neurotherapeutics.The Diagnosis and Treatment of Optic Neuritis Clinical and imaging metrics for monitoring disease progression in patients with multiple sclerosis.Interferon-beta1a for the treatment of multiple sclerosis.Analysis of NAMCS data for multiple sclerosis, 1998-2004.Use of natalizumab in multiple sclerosis: current perspectives.Cerebrospinal fluid concentrations of peptides derived from chromogranin B and secretogranin II are decreased in multiple sclerosis.MRI characteristics are predictive for CDMS in monofocal, but not in multifocal patients with a clinically isolated syndrome.Treatment of early multiple sclerosis: the value of treatment initiation after a first clinical episode.Cognition and fatigue in patients with relapsing multiple sclerosis treated by subcutaneous interferon β-1a: an observational study SKORE Outcome measures in relapsing-remitting multiple sclerosis: capturing disability and disease progression in clinical trials.Efficacy of subcutaneous interferon β-1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes.

P2860

Q21254607-AA07EAA2-23D8-4A6F-AD4A-ACA24D580C15 Q22241654-7258BF08-8D2C-40F2-B6BA-3C396507D39B Q22252598-5282A8A9-21C9-40D7-B8A7-53FE73166239 Q24185806-A00184C7-82E0-43B5-B1CA-ACB1B3C96938 Q24202108-D5A5CC96-B6B0-46D4-B4CA-F5961F210C04 Q24243043-F05F4CCB-CD2E-4590-920B-AF6729888E3D Q24652353-66F82F3D-13EA-4882-AB0F-FE7EA5661E70 Q24655514-FF3970A8-C89A-4360-9607-32F5EB0B4B89 Q26777329-CCFD93DA-2256-4B80-BB3A-40064DA8CD3E Q26777686-1322A0DA-A7D8-46D8-8FE8-B290342C7097 Q26798434-24257B83-F888-42EA-A618-1CC8853080CB Q26851940-5AD269C2-EBAD-4F5C-AC68-2F61B967DA0B Q26852672-55BA334C-97F0-461F-9443-67FEFBE361C6 Q26864418-F0D11BC2-6B18-4B79-9AE5-8CF97D643F0F Q28239752-8A46AF37-BF11-4017-8CA5-E6C1EA1C0E2D Q28388704-365D1026-BBEE-451B-B592-EA5F9F30CBC0 Q28478190-662799F9-795F-415A-84E9-7C13AB13D5F2 Q28480907-48026D92-AE67-461A-8F4B-39E13E4C87F3 Q28554434-083C652E-E82C-42A6-93BF-DD435076AF66 Q28732705-EF2413B5-9409-4B35-AB7E-0C266B735350 Q29010983-82462120-0F62-4063-8054-C8AF54C770C9 Q29039412-1BF6A4DE-3A49-4193-8151-6D68ECFD8EF9 Q30234672-CDF5FC0F-18F0-414A-A6D1-41160293170D Q30597559-D2A996C5-9BEC-4D6E-9C49-041476398030 Q30653549-D5FF0D6F-0A77-4B90-A0EB-9E5DF82586E3 Q30663606-E806A2E9-E24A-4ED4-9C0C-7F566D202F76 Q30691743-ECA5C874-90AA-4884-98CB-AC09848EC7BA Q30983557-80950D48-DF43-4F0D-A307-9EF4586D4BAF Q30989935-02C6544D-B1D4-49FF-A355-7641A96771B9 Q30995944-D7E2E7F8-D71A-41E9-9E3F-DBEAADA46C3B Q31037055-2BA7B316-460F-438A-BF7B-4C2D55EA9F7D Q31106233-ED2C2763-6383-4141-91CA-E4F1EE045AF4 Q31108210-EF020F31-181C-4796-8A63-735B0CCA44B5 Q31114633-58ED1762-59C3-4D2C-BC22-4C15A72C2D01 Q33303468-DCBDA78E-873E-49E5-8A66-3D8C65A19034 Q33449002-95511820-1243-4845-8F57-3014546B0FF3 Q33500910-A7C2D900-468B-4035-A2DD-F16173F6112D Q33589940-17412C41-534C-4351-AF45-5BF746450DF5 Q33634866-C1E7A59E-76A1-4145-8E2F-76CA20CB7D2A Q33658606-13338A68-664E-45A9-949E-EA9D7F2049DC

P2860

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study.

http://www.wikidata.org/entity/Q34515400

description

2001 nî lūn-bûn

@nan

2001 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2001 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2001年の論文

@ja

2001年論文

@yue

2001年論文

@zh-hant

2001年論文

@zh-hk

2001年論文

@zh-mo

2001年論文

@zh-tw

2001年论文

@wuu

name

Effect of early interferon tre ...... sclerosis: a randomised study.

@ast

Effect of early interferon tre ...... sclerosis: a randomised study.

@en

Effect of early interferon tre ...... sclerosis: a randomised study.

@nl

type

label

Effect of early interferon tre ...... sclerosis: a randomised study.

@ast

Effect of early interferon tre ...... sclerosis: a randomised study.

@en

Effect of early interferon tre ...... sclerosis: a randomised study.

@nl

prefLabel

Effect of early interferon tre ...... sclerosis: a randomised study.

@ast

Effect of early interferon tre ...... sclerosis: a randomised study.

@en

Effect of early interferon tre ...... sclerosis: a randomised study.

@nl

P1433

Q34515400-CCA72743-FB9B-47B4-B0AD-CC9F06D6E4CB

P1476

Q34515400-966A1554-90FC-43C7-AFE1-0F5F4E03E833

P2093

Q34515400-01726A0A-BE01-40B9-BBF8-32DB0998FA2A

Q34515400-0A5DD27E-2E4E-4D7F-94FB-8EA3FDF6753F

Q34515400-4149B5B8-CD2A-4352-B2B8-13803155EDA5

Q34515400-4983A4B8-61C1-4F94-B5C0-01A8BF0D8C99

Q34515400-707E2B36-183B-4950-8B9D-24D133356A15

Q34515400-863FBADF-886C-413C-825B-72B055219617

Q34515400-9AE5F5B1-1A12-4E83-AFB4-76D91A561B0B

Q34515400-A523958B-96AF-4CF7-B27B-126A076D19FA

Q34515400-A598AB95-8D3F-4A42-BC94-FBC7FB1F356F

Q34515400-A964AA64-5B46-4C30-8B44-81A9E6C0A368

P304

Q34515400-178D6433-BCD4-4245-A91E-42F55C12556D

P31

Q34515400-83667450-00FB-42D0-8F64-8AE0FC66E6A4

P356

Q34515400-4CD27643-4A07-4856-B605-C3DA3DDE3ED3

P407

Q34515400-36B7F466-AF4D-4E70-9A92-99CD5282C599

P433

Q34515400-0903F2E4-2899-47B3-A145-4FB4734301A7

P478

Q34515400-78526950-4F1C-4BB4-A289-8AB3B9F100DB

P50

Q34515400-5E26ACEB-4A68-4EF1-AA73-67D675FB1653

Q34515400-94151907-5FAC-4391-BD91-85247BEA4A88

P577

Q34515400-81F555D8-993C-440B-9683-EAB6B1479AA3

P5875

Q34515400-F40D9C6E-DECE-4CE3-BDA5-0AE9EFA3CDC5

P698

Q34515400-BE55ADC6-97E5-4AB5-A49C-78BC81B960F3

P921

Q34515400-845F2E86-D35D-4963-B868-96DB19A109A2

P356

S0140-6736(00)04725-5

P1433

P1476

Effect of early interferon tre ...... sclerosis: a randomised study.

@en

P2093

Early Treatment of Multiple Sclerosis Study Group

http://www.w3.org/2001/XMLSchema#string

F Barkhof

http://www.w3.org/2001/XMLSchema#string

G Comi

http://www.w3.org/2001/XMLSchema#string

G Edan

http://www.w3.org/2001/XMLSchema#string

L Durelli

http://www.w3.org/2001/XMLSchema#string

M Filippi

http://www.w3.org/2001/XMLSchema#string

M Rovaris

http://www.w3.org/2001/XMLSchema#string

O Fernández

http://www.w3.org/2001/XMLSchema#string

O R Hommes

http://www.w3.org/2001/XMLSchema#string

P Seeldrayers

http://www.w3.org/2001/XMLSchema#string

P304

1576-1582

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S0140-6736(00)04725-5

http://www.w3.org/2001/XMLSchema#string

P407

P433

9268

http://www.w3.org/2001/XMLSchema#string

P478

357

http://www.w3.org/2001/XMLSchema#string

P50

Per Soelberg Sørensen

Hans-Peter Hartung

P577

2001-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11960360

http://www.w3.org/2001/XMLSchema#string

P698

11377645

http://www.w3.org/2001/XMLSchema#string

P921

multiple sclerosis